HUVECs were transfected with 1 mg of luciferase reporter constructs, and either 20 nmoles of either 328a-3p microRNA mimic (Qiagen, Hilden, Germany, cat # 219600-MSY0000752-5 ‘CUGGCCCUCUCUGCCCUUCCGU), control mimic (Qiagen cat # 339173 -YM00479902), inhibitor (Qiagen, cat# 339121 (YI04101608), 5 ‘CUGGCCCUCUCUGCCCUUCCGU) or control inhibitor (Qiagen cat# 339125-YI00199006) using FuGENE 6 reagent according to the manufacturer’s instructions (Roche, Indianapolis, IN, USA). The media was changed after 1–2 h to serum-free media and the cells were harvested 24 h post-transfection.
Fetal bovine serum (FBS)–starved HUVECs (for 24 h) in 1 mL of medium were treated for 24 h with either 25, 50, or 100 μL of pooled human plasma from normal controls, patients with either CAD or ectasia. In separate experiments, FBS-starved HUVECs were also treated with endotoxin-free (according to the manufacturer) human recombinant HSP70 (0.5 ng/mL, StressMarq Biosciences, Victoria, BC, Australia), S100B (0.1 ng/mL) or HMGB1 (10 ng/mL, R&D Systems, Minneapolis, MN, USA).